What is the present valuation and projected CAGR of the advanced melanoma market?
The advanced melanoma market size has grown strongly in recent years. It will grow from $3.77 billion in 2024 to $4.13 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to approval of dacarbazine, development of interferon therapy, introduction of ipilimumab, adoption of radiation therapy, emergence of combination therapies, approval of nivolumab and launch of pembrolizumab.
The advanced melanoma market size is expected to see strong growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to development of novel checkpoint inhibitors, rise in personalized medicine, progress in adoptive cell therapy, increasing use of combination therapies, emergence of bispecific antibodies, expansion of oncolytic virotherapy and growing focus on early detection tools. Major trends in the forecast period include Al-powered diagnostic tools, mRNA-based cancer vaccines, crispr-based gene editing, oncolytic virus engineering, liquid biopsy technologies, wearable health monitoring devices, advanced imaging techniques, 3d bioprinting for research, tumor microenvironment modeling and nanotechnology-driven drug delivery systems.
Get Your Free Sample of The Global Advanced Melanoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21088&type=smp
What key drivers have fueled the advanced melanoma market’s development over the years?
The increasing number of cases of severe sunburns is expected to propel the growth of the advanced melanoma market going forward. Severe sunburns are intense skin burns caused by excessive exposure to ultraviolet (UV) radiation, resulting in redness, pain, swelling, and sometimes blistering. The increasing number of severe sunburn cases is due to prolonged exposure to ultraviolet (UV) radiation, lack of proper sun protection measures, increased outdoor activities during peak UV hours, and rising temperatures due to climate change. Severe sunburns, especially those occurring repeatedly or at a young age, cause DNA damage in skin cells, which can lead to genetic mutations that trigger melanoma. For instance, in May 2024, according to Melanoma Focus, a UK-based charity dedicated to supporting the melanoma community, in 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 babies under one-year-old. Further, 66% of UK adults aged 16-65 remembered getting sunburned as children, and 65% experienced severe sunburn with blisters at least once. This number rose to 77% for those with light, pale, or white skin. Therefore, the increasing number of cases of severe sunburns is driving the growth of the advanced melanoma market.
What is the segmentation for the advanced melanoma market?
The advanced melanoma market covered in this report is segmented –
1) By Therapeutics: Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By End-User: Hospitals, Cancer Research Centres, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs
2) By Biological Therapy: Monoclonal Antibodies, Interferons, Interleukins
3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies
4) By Immune Therapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, Adoptive Cell Transfer
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/advanced-melanoma-global-market-report
Who are the most influential companies in the advanced melanoma market?
Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma
What are the top industry trends projected to impact the advanced melanoma market?
Major companies operating in the advanced melanoma market are focusing on developing innovative products, such as personalized vaccines, to improve treatment efficacy, overcome resistance mechanisms, and provide personalized treatment options that can lead to better patient outcomes and prolonged survival. A personalized vaccine for advanced melanoma is a type of cancer treatment designed specifically for an individual patient based on the unique genetic mutations in their tumor. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) scheme designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, when used in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection. The personalized cancer vaccine mRNA-4157/V940 comprises a single synthetic mRNA coding for up to 34 neoantigens and is designed and produced based on the unique mutational signature of the patient’s tumor.
What are the major regional insights for the advanced melanoma market, and which region holds the top position?
North America was the largest region in the advanced melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced melanoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Advanced Melanoma Market Report 2025 Offer?
The advanced melanoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Advanced melanoma refers to melanoma skin cancer that has spread beyond the original site to other parts of the body. It includes stage III (spread to nearby lymph nodes) and stage IV (metastasized to distant organs l), which is more challenging to treat and often requires a combination of therapies, such as immunotherapy, targeted therapy, chemotherapy, or radiation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21088
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
